Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a JAK1/2 inhibitor for the treatment of a cancer, such as a hematological cancer, in a subject in need thereof. Also provided herein are methods for treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a JAK1/2 inhibitor.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
September 6, 2022
Assignee:
University of Modena and Reggio Emilia
Inventors:
Samantha Pozzi, Maria Cosenza, Monica Civallero
Abstract: The invention relates to pharmaceutical combinations comprising an HDAC inhibitor and bendamustine; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions for treating lymphoma in a subject in need thereof.